Search

In DNA vaccines, the gene of interest is cloned into a bacterial plasmid that is engineered to induce protein production for long periods in eukaryotic cells. Previous research has shown that the intramuscular immunization of BALB/c mice with a naked plasmid DNA fragment encoding the Mycobacterium leprae 65-kDa heat-shock protein (pcDNA3-Hsp65) induces protection against M. tuberculosis challenge. A key stage in the protective immune response after immunization is the generation of memory T cells. Previously, we have shown that B cells capture plasmid DNA-Hsp65 and thereby modulate the formation of CD8+ memory T cells after M. tuberculosis challenge in mice. Therefore, clarifying how B cells act as part of the protective immune response after DNA immunization is important for the development of more-effective vaccines. The aim of this study was to investigate the mechanisms by which B cells modulate memory T cells after DNA-Hsp65 immunization. C57BL/6 and BKO mice were injected three times, at 15-day intervals, with 100 µg naked pcDNA-Hsp65 per mouse. Thirty days after immunization, the percentages of effector memory T (TEM) cells (CD4+ and CD8+/CD44high/CD62Llow) and memory CD8+ T cells (CD8+/CD44high/CD62Llow/CD127+) were measured with flow cytometry. Interferon γ, interleukin 12 (IL-12), and IL-10 mRNAs were also quantified in whole spleen cells and purified B cells (CD43-) with real-time qPCR. Our data suggest that a B-cell subpopulation expressing IL-10 downregulated proinflammatory cytokine expression in the spleen, increasing the survival of CD4+ TEM cells and CD8+ TEM/CD127+ cells.

In the last several years, the use of dendritic cells has been studied as a therapeutic strategy against tumors. Dendritic cells can be pulsed with peptides or full-length protein, or they can be transfected with DNA or RNA. However, comparative studies suggest that transfecting dendritic cells with messenger RNA (mRNA) is superior to other antigen-loading techniques in generating immunocompetent dendritic cells. In the present study, we evaluated a new therapeutic strategy to fight tuberculosis using dendritic cells and macrophages transfected with Hsp65 mRNA. First, we demonstrated that antigen-presenting cells transfected with Hsp65 mRNA exhibit a higher level of expression of co-stimulatory molecules, suggesting that Hsp65 mRNA has immunostimulatory properties. We also demonstrated that spleen cells obtained from animals immunized with mock and Hsp65 mRNA-transfected dendritic cells were able to generate a mixed Th1/Th2 response with production not only of IFN-γ but also of IL-5 and IL-10. In contrast, cells recovered from mice immunized with Hsp65 mRNA-transfected macrophages were able to produce only IL-5. When mice were infected with Mycobacterium tuberculosis and treated with antigen-presenting cells transfected with Hsp65 mRNA (therapeutic immunization), we did not detect any decrease in the lung bacterial load or any preservation of the lung parenchyma, indicating the inability of transfected cells to confer curative effects against tuberculosis. In spite of the lack of therapeutic efficacy, this study reports for the first time the use of antigen-presenting cells transfected with mRNA in experimental tuberculosis.

Tuberculosis (TB) is a major public health concern worldwide; however the factors that account for resistance or susceptibility to disease are not completely understood. Although some studies suggest that the differential expression of miRNAs in peripheral blood of TB patients could be useful as biomarkers of active disease, their involvement during the inflammatory process in lungs of infected individuals is unknown. Here, we evaluated the global expression of miRNAs in the lungs of mice experimentally infected with Mycobacterium tuberculosis on 30 and 60 days post-infection. We observed that several miRNAs were differentially expressed compared to uninfected mice. Furthermore, we verified that the expression of miR-135b, miR-21, miR-155, miR-146a, and miR-146b was significantly altered in distinct leukocyte subsets isolated from lungs of infected mice, while genes potentially targeted by those miRNAs were associated with a diversity of immune related molecular pathways. Importantly, we validated the inhibition of Pellino 1 expression by miR-135b in vitro. Overall, this study contributes to the understanding of the dynamics of miRNA expression in lungs during experimental TB and adds further perspectives into the role of miRNAs on the regulation of immune processes such as leukocyte activation.

Os virus sao responsaveis por milhares de mortes no mundo todos os anos. O HIV (Virus da Imunodeficiencia Humana) e atualmente o virus que causa mais mortes. No ano de 2004 causou 4,9% das mortes ocorridas no mundo (WHO 2005) e pelo menos 13320 mortes ocorridas no Brasil em 2002 (WHO 2005). Por essa razao, o estudo da interacao dos virus com sistema imune e de extrema importância. Os virus tem como caracteristica marcante a obrigatoriedade de parasitar uma celula, para iniciar e completar seu ciclo de proliferacao. Essa necessidade se da, pois os virus apenas possuem a informacao genetica minima para realizarem sua duplicacao. Essa informacao esta contida em moleculas de DNA ou RNA e para que essa informacao seja transformada em acao, isto e, para que as proteinas codificadas pelos acidos nucleicos sejam produzidas, os virus tem que necessariamente manipular e utilizar a maquinaria celular a fim de completar seu estagio de reproducao. O sistema imunologico humano tenta de diversas maneiras inibir esse ciclo, seja neutralizando os virus pela producao de anticorpos ou ativando diferentes tipos de resposta imune contra os mesmos. Nesta revisao serao abordados os aspectos mais importantes da resposta imune contra as infeccoes virais e os mecanismos que os virus utilizam para escapar dessa defesa do hospedeiro.

da Fonseca DM, Trombone APF, Repeke CE, Avila-Campos MJ, Coelho-Castelo AAM, Silva JS, Campanelli AP, Bonato VLD, Garlet GP. Functional interferences in host inflammatory immune response by airway allergic inflammation restrain experimental periodontitis development in mice. J Clin Periodontol 2011; 38: 131–141. doi: 10.1111/j.1600-051X.2010.01660.x Abstract Aims: Periodontal disease (PD) and airway allergic inflammation (AL) present opposing inflammatory immunological features and clinically present an inverse correlation. However, the putative mechanisms underlying such opposite association are unknown. Material and Methods: Balb/C mice were submitted to the co-induction of experimental PD (induced by Actinobacillus actinomycetemcomitans oral inoculation) and AL [induced by sensitization with ovalbumin (OVA) and the subsequent OVA challenges], and evaluated regarding PD and AL severity, immune response [cytokine production at periodontal tissues, and T-helper transcription factors in submandibular lymph nodes (LNs)] and infection parameters. Results: PD/AL co-induction decreased PD alveolar bone loss and periodontal inflammation while experimental AL parameters were unaltered. An active functional interference was verified, because independent OVA sensitization and challenge not modulate PD outcome. PD+AL group presented decreased tumour necrosis factor-α (TNF-α), interleukin (IL)-1β, interferon-γ, IL-17A, receptor activator of nuclear factor κ-light-chain-enhancer of activated B cells ligand and matrix metalloproteinase (MMP)-13 levels in periodontal tissues, while IL-4 and IL-10 levels were unaltered by AL co-induction. AL co-induction also resulted in upregulated T-bet and related orphan receptor γ and downregulated GATA3 levels expression in submandibular LNs when compared with PD group. Conclusion: Our results demonstrate that the interaction between experimental periodontitis and allergy involves functional immunological interferences, which restrains experimental periodontitis development by means of a skewed immune response.

Adult worms of Schistosoma mansoni live in the bloodstream, employing immune evasion strategies and exposing few antigens to the immune system. The tegumental surface of adult worms presents Sm60, a mannose-binding protein, which induces neutrophil migration and mast cell degranulation. Here we demonstrated that Sm60 is able to block the in vitro antigen-specific or polyclonal spleen cell proliferation induced by keyhole limpet haemocyanin (KLH) or con- canavalin A (Con A), respectively. To address the mechanism of inhibition, we evaluated some cytokines in culture and observed that Sm60 decreased significantly the synthesis of interleukin (IL)-2 induced in response to KLH, but not other cytokines. To block the suppression triggered by Sm60, exogenous IL-2 or α-methyl-mannoside were added to KLH- stimulated cultures pulsed with Sm60. Only IL-2 abolished the Sm60 effect, suggesting that Sm60 blocked the lymphop- roliferation through the inhibition of IL-2 production, in a carbohydrate recognition domain (CRD)-independent mecha- nism. Our results suggest that Sm60 could participate in the immune evasion mechanisms of S. mansoni.

A interação do sistema imune com os agentes infecciosos ocorre de uma maneira dinâmica, com mecanismos de controle da infecção e de escape sofisticados. A compreensão dessa complexidade é condição sine qua non para que se estabeleça uma ação total no controle dessas infecções. Embora a resposta imune desenvolvida para controle das diferentes infecções apresente certas particularidades, em geral, apresentam também mecanismos comuns. A priori os mecanismos podem ser redundantes, no entanto existe uma gama de sutilezas entre a interação hospedeiro-parasita que define o estabelecimento ou não de doença. Por outro lado, não se pode deixar de alertar que melhores condições de saneamento básico diminuiriam a incidência de inúmeras doenças. A classificação de uma resposta imune protetora tem que ser avaliada sempre em relação ao tipo de agente agressor, pois um mecanismo protetor conta um vírus pode não ser essencial contra uma bactéria extracelular. De qualquer forma, o avanço na pesquisa com diferentes patógenos tem contribuído para uma melhor compreensão da resposta imune decorrente da interação entre o hospedeiro e parasita o que pode resultar no desenvolvimento de novas drogas e vacinas.

Background The continued increase in tuberculosis (TB) rates and the appearance of extremely resistant Mycobacterium tuberculosis strains (XDR-TB) worldwide are some of the great problems of public health. In this context, DNA immunotherapy has been proposed as an effective alternative that could circumvent the limitations of conventional drugs. Nonetheless, the molecular events underlying these therapeutic effects are poorly understood. Methods We characterized the transcriptional signature of lungs from mice infected with M. tuberculosis and treated with heat shock protein 65 as a genetic vaccine (DNAhsp65) combining microarray and real-time polymerase chain reaction analysis. The gene expression data were correlated with the histopathological analysis of lungs. Results The differential modulation of a high number of genes allowed us to distinguish DNAhsp65-treated from nontreated animals (saline and vector-injected mice). Functional analysis of this group of genes suggests that DNAhsp65 therapy could not only boost the T helper (Th)1 immune response, but also could inhibit Th2 cytokines and regulate the intensity of inflammation through fine tuning of gene expression of various genes, including those of interleukin-17, lymphotoxin A, tumour necrosis factor-α, interleukin-6, transforming growth factor-β, inducible nitric oxide synthase and Foxp3. In addition, a large number of genes and expressed sequence tags previously unrelated to DNA-therapy were identified. All these findings were well correlated with the histopathological lesions presented in the lungs. Conclusions The effects of DNA therapy are reflected in gene expression modulation; therefore, the genes identified as differentially expressed could be considered as transcriptional biomarkers of DNAhsp65 immunotherapy against TB. The data have important implications for achieving a better understanding of gene-based therapies. Copyright © 2008 John Wiley & Sons, Ltd.

Mycobacterium tuberculosis and helminth infections coincide geographically and are classically described as TH1 and TH2 pathologies. There is much interest in exploring how concurrent worm infections might alter immune responses to mycobacterial infection. To explore this issue, mice were infected with Toxocara canis and co-infected with M. tuberculosis. Mice infected with M. tuberculosis had high numbers of neutrophils and mononuclear cells within the alveolar spaces, with increased parenchymal interferon (IFN)-γ levels. However, in Toxocara-infected mice we detected increased eosinophil numbers in bronchoalveolar lavage fluid (BALF) and increased parenchymal levels of interleukin (IL)-5. In co-infected mice the BALF demonstrated enhanced eosinophil influx with decreased neutrophil and mononuclear cell accumulation. However, co-infected mice had similar mycobacterial proliferation in their lungs accompanied by similar histopathological changes and similar cytokine/nitric oxide production compared with Mycobacterium-only–infected mice. Our results suggest that T. canis infection does not necessarily lead to increased susceptibility to pulmonary tuberculosis.

We described a prophylactic and therapeutic effect of a DNA vaccine encoding the Mycobacterium leprae 65-kDa heat shock protein (DNA-hsp65) in experimental murine tuberculosis. However, high homology of the vaccine to the corresponding mammalian hsp60, together with the CpG motifs in the plasmidial vector, could trigger or exacerbate an autoimmune disease. In the present study, we evaluate the potential of DNA-hsp65 vaccination to induce or modulate arthritis in mice genetically selected for acute inflammatory reaction (AIR), either maximal (AIRmax) or minimal (AIRmin). Mice immunized with DNA-hsp65 or injected with the corresponding DNA vector (DNAv) developed no arthritis, whereas pristane injection resulted in arthritis in 62% of AIRmax mice and 7.3% of AIRmin mice. Administered after pristane, DNA-hsp65 downregulated arthritis induction in AIRmax animals. Levels of interleukin (IL)-12 were significantly lower in mice receiving pristane plus DNA-hsp65 or DNAv than in mice receiving pristane alone. However, when mice previously injected with pristane were inoculated with DNA-hsp65 or DNAv, the protective effect was significantly correlated with lower IL-6 and IL-12 levels and higher IL-10 levels. Our results strongly suggest that DNA-hsp65 has no arthritogenic potential and is actually protective against experimentally induced arthritis in mice.

Nucleic acid vaccines are an attractive alternative to conventional protein vaccines because of their ability to induce de novo production of antigens in a given tissue after DNA delivery. Although DNA vaccines are highly effective in inducing both cell-mediated and humoral immunity, little is known about the many cell types involved in plasmid DNA uptake in vivo. Here we demonstrate, for the first time, that plasmid DNA can be taken up by both bone marrow and lymph node B cells after intramuscular immunization. Plasmid DNA was also detected in CD11b+ and CD11c+ cells. This phenomenon was not restricted to plasmid DNA encoding mycobacterial 65-kd heat shock protein (pcDNA3-hsp65) because we observed similar results with plasmid-encoding green fluorescent protein (GFP-pEGFP-2C). In addition to plasmid DNA uptake, B cells also express the encoded protein, suggesting that B cells play a role in the immune response after DNA immunization. The biodistribution of plasmid DNA in B cells opens a new perspective in B-cell gene therapy for the in vivo use of plasmid DNA.

We demonstrate here that a mannose-binding protein from Schistosoma mansoni, termed Sm60, was recovered in the mannose-eluted fraction (Man(+)) upon affinity chromatography on immobilised mannose of the soluble antigen fraction from adult worm tegument and cercariae. Sm60 was detected in the Man(+) fraction as a prominent doublet with an apparent molecular mass of 60-66 kDa by SDS-PAGE and appeared as a single band with a pI of approximately 6.9 by isoelectrofocusing. Sm60 was also detected in preparations of schistosomula extract and soluble egg antigens using a mouse polyclonal anti-Sm60 serum on immunoblotting assay. This antiserum demonstrated that Sm60 was localised on the tegument of S. mansoni adult worm. In order to determine the role of Sm60 in host-parasite interactions, we showed that Sm60 induced in vitro migration of human neutrophil in a dose-dependent manner and in vitro mast cell degranulation. Sm60 triggered these activities through its carbohydrate-binding site, since these activities were selectively inhibited by 0.2 M D-mannose, but not by 0.2 M D-galactose. Furthermore, Sm60 induced in vivo neutrophil migration. In contrast, mast cell-depleted rats presented a significant reduction of the neutrophil migration induced by Sm60 as compared with non-depleted controls. These data suggest that in vivo neutrophil migration induced by Sm60 is modulated by mast cell-dependent mechanisms. Sm60 might play a key role in the host-parasite interaction, and its characterization opens perspective to examine the role of this molecule in the biology of S. mansoni.

Host cell invasion by Toxoplasma gondii is a multistep process with one of the first steps being the apical release of micronemal proteins that interact with host receptors. We demonstrate here that micronemal protein 1 (MIC1) is a lactose-binding lectin. MIC1 and MIC4 were recovered in the lactose-eluted (Lac(+)) fraction on affinity chromatography on immobilized lactose of the soluble antigen fraction from tachyzoites of the virulent RH strain. MIC1 and MIC4 were both identified by N-terminal microsequencing. MIC4 was also identified by sequencing cDNA clones isolated from an expression library following screening with mouse polyclonal anti-60/70 kDa (Lac(+) proteins) serum. This antiserum localized the Lac(+) proteins on the apical region of T. gondii tachyzoites by confocal microscopy. The Lac(+) fraction induced hemagglutination (mainly type A human erythrocytes), which was inhibited by beta-galactosides (3 mM lactose and 12 mM galactose) but not by up to 100 mM melibiose (alpha-galactoside), fucose, mannose, or glucose or 0.2 mg/ml heparin. The lectin activity of the Lac(+) preparation was attributed to MIC1, because blotted MIC1, but not native MIC4, bound human erythrocyte type A and fetuin. The copurification of MIC1 and MIC4 may have been due to their association, as reported by others. These data suggest that MIC1 may act through its lectin activity during T. gondii infection.

The genus Paracoccidioides comprises species of dimorphic fungi that cause paracoccidioidomycosis (PCM), a systemic disease prevalent in Latin America. Here, we investigated whether administration of native 60-kDa heat shock protein of P. brasiliensis (nPbHsp60) or its recombinant counterpart (rPbHsp60) affected the course of experimental PCM. Mice were subcutaneously injected with nPbHsp60 or rPbHsp60 emulsified in complete's Freund Adjuvant (CFA) at three weeks after intravenous injection of P. brasiliensis yeasts. Infected control mice were injected with CFA or isotonic saline solution alone. Thirty days after the nPbHsp60 or rPbHsp60 administration, mice showed remarkably increased fungal load, tissue inflammation, and granulomas in the lungs, liver, and spleen compared with control mice. Further, rPbHsp60 treatment (i) decreased the known protective effect of CFA against PCM and (ii) increased the concentrations of IL-17, TNF-α, IL-12, IFN-γ, IL-4, IL-10, and TGF-β in the lungs. Together, our results indicated that PbHsp60 induced a harmful immune response, exacerbated inflammation, and promoted fungal dissemination. Therefore, we propose that PbHsp60 contributes to the fungal pathogenesis.

Background Although plasmid DNA encoding an antigen from pathogens or tumor cells has been widely studied as vaccine, the use of plasmid vector (without insert) as therapeutic agent requires further investigation. Results Here, we showed that plasmid DNA (pcDNA3) at low doses inhibits the production of IL-6 and TNF-α by lipopolysaccharide (LPS)-stimulated macrophage cell line J774. These findings led us to evaluate whether plasmid DNA could act as an anti-inflammatory agent in a Wistar rat endotoxemia model. Rats injected simultaneously with 1.5 mg/kg of LPS and 10 or 20 μg of plasmid DNA had a remarkable attenuation of mean arterial blood pressure (MAP) drop at 2 hours after treatment when compared with rats injected with LPS only. The beneficial effect of the plasmid DNA on MAP was associated with decreased expression of IL-6 in liver and increased concentration of plasma vasopressin (AVP), a known vasoconstrictor that has been investigated in hemorrhagic shock management. No difference was observed in relation to nitric oxide (NO) production. Conclusion Our results demonstrate for the first time that plasmid DNA vector at low doses presents anti-inflammatory property and constitutes a novel approach with therapeutic potential in inflammatory diseases.

Background mRNAs are highly versatile, non-toxic molecules that are easy to produce and store, which can allow transient protein expression in all cell types. The safety aspects of mRNA-based treatments in gene therapy make this molecule one of the most promising active components of therapeutic or prophylactic methods. The use of mRNA as strategy for the stimulation of the immune system has been used mainly in current strategies for the cancer treatment but until now no one tested this molecule as vaccine for infectious disease. Results We produce messenger RNA of Hsp65 protein from Mycobacterium leprae and show that vaccination of mice with a single dose of 10 μg of naked mRNA-Hsp65 through intranasal route was able to induce protection against subsequent challenge with virulent strain of Mycobacterium tuberculosis. Moreover it was shown that this immunization was associated with specific production of IL-10 and TNF-alpha in spleen. In order to determine if antigen presenting cells (APCs) present in the lung are capable of capture the mRNA, labeled mRNA-Hsp65 was administered by intranasal route and lung APCs were analyzed by flow cytometry. These experiments showed that after 30 minutes until 8 hours the populations of CD11c+, CD11b+ and CD19+ cells were able to capture the mRNA. We also demonstrated in vitro that mRNA-Hsp65 leads nitric oxide (NO) production through Toll-like receptor 7 (TLR7). Conclusions Taken together, our results showed a novel and efficient strategy to control experimental tuberculosis, besides opening novel perspectives for the use of mRNA in vaccines against infectious diseases and clarifying the mechanisms involved in the disease protection we noticed as well.

The conventional treatment for paracoccidioidomycosis, the most prevalent mycosis in Latin America, involves long periods of therapy resulting in sequels and high frequency of relapses. The search for new alternatives of treatment is necessary. Previously, we have demonstrated that the hsp65 gene from Mycobacterium leprae shows prophylactic effects against murine paracoccidioidomycosis. Here, we tested the DNAhsp65 immunotherapy in BALB/c mice infected with Paracoccidioides brasiliensis, the agent of paracoccidioidomycosis. We observed an increase of Th1 cytokines accompanied by a reduction in fungal burden and pulmonary injury. These results provide new prospects for immunotherapy of paracoccidioidomycosis and other mycoses.

Tuberculosis is a major threat to human health. The high disease burden remains unaffected and the appearance of extremely drug-resistant strains in different parts of the world argues in favor of the urgent need for a new effective vaccine. One of the promising candidates is heat-shock protein 65 when used as a genetic vaccine (DNAhsp65). Nonetheless, there are substantial data indicating that BCG, the only available anti-TB vaccine for clinical use, provides other important beneficial effects in immunized infants.We compared the protective efficacy of BCG and Hsp65 antigens in mice using different strategies: i) BCG, single dose subcutaneously; ii) naked DNAhsp65, four doses, intramuscularly; iii) liposomes containing DNAhsp65, single dose, intranasally; iv) microspheres containing DNAhsp65 or rHsp65, single dose, intramuscularly; and v) prime-boost with subcutaneous BCG and intramuscular DNAhsp65.All the immunization protocols were able to protect mice against infection, with special benefits provided by DNAhsp65 in liposomes and prime-boost strategies.Among the immunization protocols tested, liposomes containing DNAhsp65 represent the most promising strategy for the development of a new anti-TB vaccine.

We present a comparative study of the physico-chemical properties, in vitro cytotoxicity and in vivo antibody production of surface-complexed DNA in EPC/DOTAP/DOPE (50/25/25% molar) liposomes and DOTAP/DOPE (50/50% molar) lipoplexes. The study aims to correlate the biological behavior and structural properties of the lipid carriers. We used DNA-hsp65, whose naked action as a gene vaccine against tuberculosis has already been demonstrated. Additionally, surface-complexed DNA-hsp65 in EPC/DOTAP/DOPE (50/25/25% molar) liposomes was effective as a single-dose tuberculosis vaccine. The results obtained showed that the EPC inclusion stabilized the DOTAP/DOPE structure, producing higher melting temperature and lower zeta potential despite a close mean hydrodynamic diameter. Resemblances in morphologies were identified in both structures, although a higher fraction of loaded DNA was not electrostatically bound in EPC/DOTAP/DOPE. EPC also induced a striking reduction in cytotoxicity, similar to naked DNA-hsp65. The proper immune response lead to a polarized antibody production of the IgG2a isotype, even for the cytotoxic DOTAP/DOPE. However, the antibody production was detected at 15 and 30 days for DOTAP/DOPE and EPC/DOTAP/DOPE, respectively. Therefore, the in vivo antibody production neither correlates with the in vitro cytotoxicity, nor with the structural stability alone. The synergistic effect of the structural stability and DNA electrostatic binding upon the surface of structures account for the immunological effects. By adjusting the composition to generate proper packing and cationic lipid/DNA interaction, we allow for the optimization of liposome formulations for required immunization or gene therapy. In a specific manner, our results contribute to studies on the tuberculosis therapy and vaccination.

Background A number of reports have demonstrated that rodents immunized with DNA vaccines can produce antibodies and cellular immune responses presenting a long-lasting protective immunity. These findings have attracted considerable interest in the field of DNA vaccination. We have previously described the prophylactic and therapeutic effects of a DNA vaccine encoding the Mycobacterium leprae 65 kDa heat shock protein (DNA-HSP65) in a murine model of tuberculosis. As DNA vaccines are often less effective in humans, we aimed to find out how the DNA-HSP65 stimulates human immune responses. Methods To address this question, we analysed the activation of both human macrophages and dendritic cells (DCs) cultured with DNA-HSP65. Then, these cells stimulated with the DNA vaccine were evaluated regarding the expression of surface markers, cytokine production and microbicidal activity. Results It was observed that DCs and macrophages presented different ability to uptake DNA vaccine. Under DNA stimulation, macrophages, characterized as CD11b+/CD86+/HLA-DR+, produced high levels of TNF-alpha, IL-6 (pro-inflammatory cytokines), and IL-10 (anti-inflammatory cytokine). Besides, they also presented a microbicidal activity higher than that observed in DCs after infection with M. tuberculosis. On the other hand, DCs, characterized as CD11c+/CD86+/CD123-/BDCA-4+/IFN-alpha-, produced high levels of IL-12 and low levels of TNF-alpha, IL-6 and IL-10. Finally, the DNA-HSP65 vaccine was able to induce proliferation of peripheral blood lymphocytes. Conclusion Our data suggest that the immune response is differently activated by the DNA-HSP65 vaccine in humans. These findings provide important clues to the design of new strategies for using DNA vaccines in human immunotherapy.

Submitted by Vitor Silverio Rodrigues (vitorsrodrigues@reitoria.unesp.br) on 2014-05-27T11:22:39Z No. of bitstreams: 0Bitstream added on 2014-05-27T14:29:55Z : No. of bitstreams: 1 2-s2.0-38949193197.pdf: 345078 bytes, checksum: 55ba86a1ab3942619638fa0903a67433 (MD5) Made available in DSpace on 2014-05-27T11:22:39Z (GMT). No. of bitstreams: 0 Previous issue date: 2007-11-29 Background: Vaccination of neonates is generally difficult due to the immaturity of the immune system and consequent higher susceptibility to tolerance induction. Genetic immunization has been described as an alternative to trigger a stronger immune response in neonates, including significant Th1 polarization. In this investigation we analysed the potential use of a genetic vaccine containing the heat shock protein (hsp65) from Mycobacterium leprae (pVAXhsp65) against tuberculosis (TB) in neonate mice. Aspects as antigen production, genomic integration and immunogenicity were evaluated. Methods: Hsp65 message and genomic integration were evaluated by RT-PCR and Southern blot, respectively. Immunogenicity of pVAXhsp65 alone or combined with BCG was analysed by specific induction of antibodies and cytokines, both quantified by ELISA. Results: This DNA vaccine was transcribed by muscular cells of neonate mice without integration into the cellular genome. Even though this vaccine was not strongly immunogenic when entirely administered (three doses) during early animal's life, it was not tolerogenic. In addition, pVAXhsp65 and BCG were equally able to prime newborn mice for a strong and mixed immune response (Th1 + Th2) to pVAXhsp65 boosters administered later, at the adult life. Conclusion: These results suggest that pVAXhsp65 can be safely used as a priming stimulus in neonate animals in prime-boost similar strategies to control TB. However, priming with BCG or pVAXhsp65, directed the ensuing immune response triggered by an heterologous or homologous booster, to a mixed Th1/Th2 pattern of response. Measures as introduction of IL-12 or GM-CSF genes in the vaccine construct or even IL-4 neutralization, are probably required to increase the priming towards Th1 polarization to ensure control of tuberculosis infection. © 2007 Pelizon et al; licensee BioMed Central Ltd. Department of Microbiology and Immunology Biosciences Institute São Paulo State University (UNESP), Botucatu, São Paulo 18618-000 Department of Morphology Biosciences Institute São Paulo State University (UNESP), Botucatu, São Paulo 18618-000 Department of Biochemistry and Immunology University of São Paulo (USP), Ribeirão Preto, São Paulo 14049-900 Department of Microbiology and Immunology Biosciences Institute São Paulo State University (UNESP), Botucatu, São Paulo 18618-000 Department of Morphology Biosciences Institute São Paulo State University (UNESP), Botucatu, São Paulo 18618-000

BACKGROUND: Experimental models using DNA vaccine has shown that this vaccine is efficient in generating humoral and cellular immune responses to a wide variety of DNA-derived antigens. Despite the progress in DNA vaccine development, the intracellular transport and fate of naked plasmid DNA in eukaryotic cells is poorly understood, and need to be clarified in order to facilitate the development of novel vectors and vaccine strategies. METHODOLOGY AND PRINCIPAL FINDINGS: Using confocal microscopy, we have demonstrated for the first time that after plasmid DNA uptake an inhibition of the acidification of the lysosomal compartment occurs. This lack of acidification impaired antigen presentation to CD4 T cells, but did not alter the recruitment of MyD88. The recruitment of Rab 5 and Lamp I were also altered since we were not able to co-localize plasmid DNA with Rab 5 and Lamp I in early endosomes and late endosomes/lysosomes, respectively. Furthermore, we observed that the DNA capture process in macrophages was by clathrin-mediated endocytosis. In addition, we observed that plasmid DNA remains in vesicles until it is in a juxtanuclear location, suggesting that the plasmid does not escape into the cytoplasmic compartment. CONCLUSIONS AND SIGNIFICANCE: Taken together our data suggests a novel mechanism involved in the intracellular trafficking of plasmid DNA, and opens new possibilities for the use of lower doses of plasmid DNA to regulate the immune response.

Submitted by Vitor Silverio Rodrigues (vitorsrodrigues@reitoria.unesp.br) on 2014-05-27T11:21:48Z No. of bitstreams: 0Bitstream added on 2014-05-27T14:29:34Z : No. of bitstreams: 1 2-s2.0-33645016634.pdf: 615364 bytes, checksum: 3cbbb8ce140e63aacc964262c2e48ff8 (MD5) Made available in DSpace on 2014-05-27T11:21:48Z (GMT). No. of bitstreams: 0 Previous issue date: 2006-01-30 In order to assess a new strategy of DNA vaccine for a more complete understanding of its action in immune response, it is important to determine the in vivo biodistribution fate and antigen expression. In previous studies, our group focused on the prophylactic and therapeutic use of a plasmid DNA encoding the Mycobacterium leprae 65-kDa heat shock protein (Hsp65) and achieved an efficient immune response induction as well as protection against virulent M. tuberculosis challenge. In the present study, we examined in vivo tissue distribution of naked DNA-Hsp65 vaccine, the Hsp65 message, genome integration and methylation status of plasmid DNA. The DNA-Hsp65 was detectable in several tissue types, indicating that DNA-Hsp65 disseminates widely throughout the body. The biodistribution was dose-dependent. In contrast, RT-PCR detected the Hsp65 message for at least 15 days in muscle or liver tissue from immunized mice. We also analyzed the methylation status and integration of the injected plasmid DNA into the host cellular genome. The bacterial methylation pattern persisted for at least 6 months, indicating that the plasmid DNA-Hsp65 does not replicate in mammalian tissue, and Southern blot analysis showed that plasmid DNA was not integrated. These results have important implications for the use of DNA-Hsp65 vaccine in a clinical setting and open new perspectives for DNA vaccines and new considerations about the inoculation site and delivery system. © 2006 Coelho-Castelo et al; licensee BioMed Central Ltd. Departamento de Bioquímica e Imunologia Faculdade de Medicina Universidade de São Paulo, Ribeirão Preto, SP REDE-TB: Rede Brasileira de Combate à Tuberculose USP, Riberiao Preto, São Paulo Instituto de Biociências UNESP, Botucatu, São Paulo Instituto de Biociências UNESP, Botucatu, São Paulo

Tuberculosis (TB) remains a threat for public health, killing around 3 million people a year. Despite the fact that most cases can be cured with antibiotics, the treatment is long and patients relapse if chemotherapy is not continued for at least 6 months. Thus, a better characterization of the working principles of the immune system in TB and identification of new immunotherapeutic products for the development of shorter regimens of treatment are essential to achieve an effective management of this disease. In the present work, we demonstrate that immunotherapy with a plasmid DNA encoding the Mycobacterium leprae 65 kDa heat-shock protein (hsp65) in order to boost the efficiency of the immune system, is a valuable adjunct to antibacterial chemotherapy to shorten the duration of treatment, improve the treatment of latent TB infection and be effective against multidrug-resistant bacilli (MDR-TB). We also showed that the use of DNA-hsp65 alone or in combination with other drugs influence the pathway of the immune response or other types of inflammatory responses and should augment our ability to alter the course of immune response/inflammation as needed, evidencing an important target for immunization or drug intervention.

Submitted by Vitor Silverio Rodrigues (vitorsrodrigues@reitoria.unesp.br) on 2014-05-27T11:21:08Z No. of bitstreams: 0Bitstream added on 2014-05-27T14:34:11Z : No. of bitstreams: 1 2-s2.0-4444271905.pdf: 448442 bytes, checksum: b7bce4a171bd524265b6639fd8817104 (MD5) Made available in DSpace on 2014-05-27T11:21:08Z (GMT). No. of bitstreams: 0 Previous issue date: 2004-09-01 A DNA vaccine based on the heat-shock protein 65 Mycobacterium leprae gene (pHSP65) presented a prophylactic and therapeutic effect in an experimental model of tuberculosis. In this paper, we addressed the question of which protective mechanisms are activated in Mycobacterium tuberculosis-infected mice after immune therapy with pHSP65. We evaluated activation of the cellular immune response in the lungs of infected mice 30 days after infection (initiation of immune therapy) and in those of uninfected mice. After 70 days (end of immune therapy), the immune responses of infected untreated mice, infected pHSP65-treated mice and infected pCDNA3-treated mice were also evaluated. Our results show that the most significant effect of pHSP65 was the stimulation of CD8+ lung cell activation, interferon-γ recovery and reduction of lung injury. There was also partial restoration of the production of tumour necrosis factor-α. Treatment with pcDNA3 vector also induced an immune stimulatory effect. However, only infected pHSP65-treated mice were able to produce significant levels of interferon-γ and to restrict the growth of bacilli. TB Network Dept. of Biochemistry and Immunology University of São Paulo Department of Pathology Ribeirão Preto Sch. of Med. University of São Paulo Dept. of Microbiology and Immunology Biosciences Institute São Paulo State University Dept. of Biochemistry and Immunology Ribeirão Preto Sch. of Med. University of São Paulo, Avenida Bandeirantes, 3900, 14049-900, Ribeirão Preto, SP Dept. of Microbiology and Immunology Biosciences Institute São Paulo State University

Vacinas de DNA, ainda em fase de experimentação e testes clínicos, podem se tornar uma importante ferramenta de combate a doenças infecciosas para as quais, até hoje, não existe prevenção segura e eficaz, como a tuberculose. Nos últimos anos vários estudos têm sido dedicados ao desenvolvimento de vacinas de DNA que codificam proteínas de micobactérias, entre as quais destacam-se as que codificam o antígeno 85 (Ag 85) e a proteína de choque térmico de 65 kDa (hsp65). Estes dois antígenos foram os mais estudados apresentando resultados bastante satisfatórios em ensaios pré-clínicos e com grande volume de dados registrados na literatura. Além de proteger contra infecção experimental por Mycobacterium tuberculosis virulenta, a vacina DNA-hsp65 também apresenta atividade terapêutica, ou seja, é capaz de curar os animais previamente infectados, inclusive aqueles com bacilos resistentes a múltiplas drogas. Esta vacina, hoje em avaliação clínica no Brasil também para o tratamento de câncer, é capaz de induzir a produção de citocinas de padrão Th1 tal como IFN- interferon-gama, associadas ao controle da doença. Além disso, a vacina de DNA-hsp65 é capaz de estimular clones de células CD8 citotóxicos e CD4 que podem ser caracterizados como células de memória sendo responsáveis por conferir imunidade duradoura contra a infecção. Quando utilizada na terapia da infecção, a vacina de DNA-hsp65 faz com que haja uma mudança no padrão de resposta imune, induzindo a secreção de citocinas de padrão Th1 criando um ambiente favorável à erradicação do bacilo. Os resultados demonstram ainda que a via de administração e a formulação na qual a vacina é administrada exerce fundamental influência no padrão e duração da resposta imune desencadeada. O conjunto de resultados hoje disponíveis mostra que uma vacina de DNA contra a tuberculose contribuirá de maneira significativa no controle desta doença.

The high incidence of tuberculosis around the world and the inability of BCG to protect certain populations clearly indicate that an improved vaccine against tuberculosis is needed. A single antigen, the mycobacterial heat shock protein hsp65, is sufficient to protect BALB/c mice against challenge infection when administered as DNA vaccine in a three-dose-based schedule. In order to simplify the vaccination schedule, we coencapsulated hsp65-DNA and trehalose dimicolate (TDM) into biodegradable poly(DL-lactide-co-glycolide) (PLGA) microspheres. BALB/c mice immunized with a single dose of DNA-hsp65/TDM-loaded microspheres produced high levels of IgG2a subtype antibody and high amounts of IFN-gamma in the supernatant of spleen cell cultures. DNA-hsp65/TDM-loaded microspheres were also able to induce high IFN-gamma production in bulk lung cells from challenged mice and confer protection as effective as that attained after three doses of naked DNA administration. This new formulation also allowed a ten-fold reduction in the DNA dose when compared to naked DNA. Thus, this combination of DNA vaccine and adjuvants with immunomodulatory and carrier properties holds the potential for an improved vaccine against tuberculosis.

The way to deliver antigens and cellular requirements for long-lasting protection against tuberculosis are not known. Immunizations with mycobacterial 65 kDa heat shock protein (hsp65) expressed from J774-hsp65 cells (antigen-presenting cells that endogenously produce hsp65 antigen) or from plasmid DNA, or with the protein entrapped in cationic liposomes, can each give protective immunity similar to that obtained from live Bacillus Calmette Guerin (BCG), whereas injecting the protein in Freund's incomplete adjuvant (FIA) has minimal effect. Protective procedures elicited high frequencies of antigen-reactive T cells with CD4 + /CD8 − and CD8 + /CD4 − phenotypes. Protection correlated with the abundance of hsp65-dependent cytotoxic CD8 + /CD4 − /CD44 hi cells. The frequency of these cells and the level of protection declined during 8 months after J774-hsp65 or liposome-mediated immunization with hsp65 protein but were sustained or steadily increased over this period after hsp65-DNA or BCG immunizations. IFN- predominated over IL-4 among the hsp65-reactive CD8 + /CD4 − and CD4 + /CD8 − populations after J774-hsp65-, hsp65-liposome-, and hsp65-DNA-mediated immunizations, but similar levels of these cytokines prevailed after BCG vaccination. © 2001 Elsevier Science Ltd. All rights reserved.

How the immune system kills Mycobacterium tuberculosis is still a puzzle. The classical picture of killing due to phagocytosis by activated macrophages may be only partly correct. Based on recent evidence, we express here the view that cytotoxic T lymphocytes also make an important contribution and suggest that DNA vaccines might be a good way to enhance this.

Approximately 2.0 x 10 cDNA clones of an Schistosoma mansoni lambda gt11 cDNA library were screened in duplicate with serum from infected mice corresponding to distinct phases of infection. A cDNA clone (7/1) was isolated and recognized only by seven week serum. The clone was subcloned in pGEX-2T and Western-blot studies showed a specific antigenic expression confirming that only serum from the chronic phase is capable of recognizing this antigen. Dot-hybridization with RNA from different developmental phases of the parasite showed that the corresponding 7/1 RNA is expressed in all phases of parasite development in vertebrate hosts.

BackgroundThe greatest challenges in vaccine development include optimization of DNA vaccines for use in humans, creation of effective single-dose vaccines, development of delivery systems that do not involve live viruses, and the identification of effective new adjuvants. Herein, we describe a novel, simple technique for efficiently vaccinating mice against tuberculosis (TB). Our technique consists of a single-dose, genetic vaccine formulation of DNA-hsp65 complexed with cationic liposomes and administered intranasally.ResultsWe developed a novel and non-toxic formulation of cationic liposomes, in which the DNA-hsp65 vaccine was entrapped (ENTR-hsp65) or complexed (COMP-hsp65), and used to immunize mice by intramuscular or intranasal routes. Although both liposome formulations induced a typical Th1 pattern of immune response, the intramuscular route of delivery did not reduce the number of bacilli. However, a single intranasal immunization with COMP-hsp65, carrying as few as 25 μg of plasmid DNA, leads to a remarkable reduction of the amount of bacilli in lungs. These effects were accompanied by increasing levels of IFN-γ and lung parenchyma preservation, results similar to those found in mice vaccinated intramuscularly four times with naked DNA-hsp65 (total of 400 μg).ConclusionOur objective was to overcome the significant obstacles currently facing DNA vaccine development. Our results in the mouse TB model showed that a single intranasal dose of COMP-hsp65 elicited a cellular immune response that was as strong as that induced by four intramuscular doses of naked-DNA. This formulation allowed a 16-fold reduction in the amount of DNA administered. Moreover, we demonstrated that this vaccine is safe, biocompatible, stable, and easily manufactured at a low cost. We believe that this strategy can be applied to human vaccines to TB in a single dose or in prime-boost protocols, leading to a tremendous impact on the control of this infectious disease.

This study aimed to demonstrate that microspheres, used as delivery vehicle of DNA-Hsp65/TDM [plasmid DNA encoding heat shock protein 65 (Hsp65) coencapsulated with trehalose dimycolate (TDM) into PLGA microspheres], are widely spread among several organs after intramuscular administration in BALB/c mice. In general, we showed that these particles were phagocytosed by antigen presenting cells, such as macrophages and dendritic cells. Besides, it was demonstrated herein that draining lymph node cells presented a significant increase in the number of cells expressing costimulatory molecules (CD80 and CD86) and MHC class II, and also that the administration of the DNA-Hsp65/TDM and vector/TDM formulations resulted in the up-regulation of CD80, CD86 and MHC class II expression when compared to control formulations (vector/TDM and empty). Regarding the intracellular trafficking we observed that following phagocytosis, the microspheres were not found in the late endosomes and/or lysosomes, until 15 days after internalization, and we suggest that these constructions were hydrolysed in early compartments. Overall, these data expand our knowledge on PLGA [poly (lactic-co- glycolic acid)] microspheres as gene carriers in vaccination strategies, as well as open perspectives for their potential use in clinical practice.

Nosso grupo demonstrou que a captura de baixas doses de DNA plasmideal pode inibir a apresentação de antígeno e induzir um padrão de resposta anti-inflamatória, e que após a captação do DNA plasmideal por macrófagos, estas moléculas podiam prevenir a acidificação de vesículas endossomais, um passo essencial para a apresentação de antígenos para células T CD4+. Além disso, em modelos in vivo, a baixa dose de DNA foi suficiente para amenizar o quadro inflamatório e diminuir a produção de citocinas inflamatórias. Estes resultados estão em contraste com os modelos de vacinas gênicas comumente utilizadas. A baixa dose de DNA plasmideal, no contexto da indução da resposta imune, pode levar à modificação na apresentação do antígeno e ativação celular levando ao controle da resposta imune exacerbada desencadeada por outro antígeno, tornando o tratamento por DNA um importante foco de estudo para o combate de doenças autoimunes e inflamações. O objetivo deste trabalho foi identificar os microRNAs expressos em macrófagos tratados com alta ou baixa dose de DNA plasmideal e avaliar o papel destas moléculas na modulação da cascata de sinalização intracelular visando esclarecer o mecanismo imunomodulador observado. Macrófagos da linhagem J774 foram estimulados por 2 horas com o vetor plasmideal pcDNA3, nas concentrações de 10 g ou 100 g de pcDNA3/mL de RPMI. O RNA total foi extraído e o ensaio de microarray para microRNAs foi realizado. Os miRNAs diferencialmente expressos foram confirmados pela RT-qPCR, e o programa de bioinformática miRDB foi utilizado para predição de genes alvos. Os miRNAs e genes selecionados também foram dosados em macrófagos estimulados com LPS e tratados com pcDNA3. Foram detectados 6 miRNAs (miR-494-3p, miR-21-3p, miR-1897-5p, miR-1894-3p, miR-294-3p e miR-483-5p) diferencialmente expressos em macrófagos estimulados somente com pcDNA3. A expressão do miR-494-3p foi aumentado somente em células tratadas com DNA em baixa concentração tanto na ausência quanto presença de LPS. O gene IBk (IKK-) foi identificado como alvo do miR-494-3p, dosado e teve sua função detectada por western blot, mostrando que seu papel biológico foi alterado na presença deste miRNA. Além disso, os dados do tratamento com pcDNA3 em camundongos knockout para o receptor TLR9, sugerem que a expressão do miR-494-3p é independente deste tipo de receptor, porém é inibida na presença do mesmo quando no tratamento com alta dose de DNA. Os dados sugerem que quando macrófagos são tratados com baixa dose de DNA plasmideal (10 g/mL), o miR-494-3p age como regulador negativo do fator de transcrição NF-B, por meio da inibição da expressão e função da proteína IKK-. Our group demonstrated that the capture of low doses of plasmid DNA can inhibit antigen presentation and induce an anti-inflammatory response pattern together with the decrease of pro-inflammatory cytokines expression, as observed in in vivo experimental models. Moreover, we observed that after the uptake of plasmid DNA by macrophages, these molecules could prevent endosomal vesicles acidification, an essential step for antigen presentation to CD4+ T cell. These results are in contrast with the usual DNA vaccines models commonly used. The low dose of plasmid DNA, in the context of immune response induction, can take to a modification in antigen presentation leading to the control of the response already established, what can be a potential treatment in auto-immune diseases and inflammation. The objective of this work is to identify expressed microRNAs on J774 macrophages triggered by different concentrations of plasmid DNA stimuli in order to evaluate the observed immunomodulatory mechanism. J774 macrophages were treated with low (10 µg/mL) and high (100 µg/mL) doses of pcDNA3 for 2 hours. Total RNA was extracted and microarray (Agilent plataform) was performed for detection of differentially expressed microRNAs. All obtained data was normalized in Genespring GX11.5 software. The microRNAs expression was confirmed by RT-qPCR and their mRNA targets were predicted by miRDB software. The miRNAs and their respective targets were also evaluated on DNA and LPS-treated macrophages. We detected 6 differentially expressed microRNAs (miR-494-3p, miR-21-3p, miR-1897-5p, miR-1894-3p, miR-294-3p e miR-483-5p) between the two conditions (fold change 2, p-value 0,05). The miR-494-3p expression increased only in cells treated with low dose of pcDNA3, on either previously LPS-stimulated cells or not. IBk (IKK-) was one of the predicted targets for miR-494-3p. RT-qPCR was performed to calculate its expression and its biological function was assessed by western blot. Besides, results from pcDNA3-treated cells from TLR9 knockout mice suggest that miR-494-3p expression is TLR9 independent although the receptor presence impaired miR-494-3p expression on high dose of pcDNA3-treated cells. Together, the data indicate that when macrophages are treated with low dose of plasmid DNA, miR-494-3p expression is increased, acting as negative regulator of the transcription factor NF-B, through IKK- inhibition.

No Brasil, e em outros paises de clima tropical, os carrapatos se tornaram um enorme problema economico de^$de que a industria do gado se desenvolveu. O carrapato Boophilus microplus, um dos artropodes mais importantes na veterinaria, causa efeitos direto, como suc,cao de sangue, e indireto, como a transmissao de uma grande variedade de patogenos que normalmente resulta em infec,c~es letais. As vacinas genicas contendo o antigeno Bm86, uma proteina ligada a membrana do intestino do carrapato B. microplus, representam uma alternativa atrativa aos acaricidas para controlar as infesta~oes por carrapatos em contrapartida aos inconvenientes produtos quimicos. Devido sua administra,cao ser feita em 4 doses no primeiro ano, seguida de refor,cos a cada seis meses, estas formula,coes vacinais nao s3c adequadas para paises com cria,cao extensiva de gado, como no Brasil. Visando uma libera~ao sustentada do antigeno Bm86, neste trabalho desenvolveuse uma vacina de dose unica baseada em microesferas polimericas. Para obter o padrao de liberac,ao desejavel, diferentes formula,coes e parametros de processo foram variados, como a composi,cao do polimero, a taxa entre os monomeros ^Uacido latico:acido glicolico\" e o tamanho das microparticulas. As formula,coes foram preparadas pelo metodo de emulsao multipla e evapora,cao do solvente. A formula~ao que melhor se enquadrou nos objetivos da vacina de dose unica foi preparada com PLGA 75:25, solu,cao 3% de PVA como estabilizante, agita,cao de 11000 rpm para forma,cao da emulsao primaria e de 800 rpm para forma,cao da emulsao multipla e evapora,cao do solvente. As particulas assim obtidas apresentaram um tamanho medio de 25 ,um, uma taxa de encapsula,cao maior que 90% e aproximadamente 50% da proteina foi liberada in vitro em 60 dias. Analises por SDS-PAGE e Westem Bloning revelaram que a proteina se manteve integra apos encapsula,cao. Os resultados da avalia,cao da imunogenicidade em bovinos mostraram que a formula,cao baseada em microesferas polimericas biodegradaveis e habil a conseguir, com uma unica dose, uma resposta imune similar aquela conseguida com tres doses das formula,coes convencionais da vacina de Bm86. In Brazil, and in others tropical countries, the ticks have become a huge economic problem since the industry of livestock has developed. Ticks and tick-borne diseases affect animal and human health and are the cause of significant economic losses. The cattle tick Boophilus microplus is one of the most important arthropods in veterinary. This tick species causes both direct effects, such as blood sucking, and indirect effects, such as transmission of a wide variety of pathogens, which usually result in lethal infections. The gene vaccines based on Bm86 antigen, a midgut membrane-bound protein of the cattle tick B. microplus, represent a good alternative to control tick infestations, compared to chemicals. However, due to these vaccine formulations need 4 doses over the first year with booster at each 6 months to be effective, they are not suitable for countries with extensive cattle raising, like Brazil. Aiming a sustained release of Bm86 antigen, in this work we developed a single shot vaccine based on Bm86 loaded polymeric microspheres. In order to obtain desired release patterns, different formulations and processing parameters were varied, for example, the composition of the polymer, the monomer ratio lactic acid:glycolic acid and the size of the microparticles. The formulations were prepared by solvent evaporation method based on double emulsion. The formulation that presented better result as single shot vaccine was prepared with PLGA 75:25, solution 3% of PVA as stabilizer, agitation of 11000 rpm to form the primary emulsion and 800 rpm to obtain the double emulsion and solvent evaporation. The particles thus obtained presented an average size of 25 m, encapsulation ratio greater than 90% and approximately 50% of the protein was released in vitro in 60 days. Analysis by SDSPAGE and Western Blot showed that the integrity of the protein remained after encapsulation. The immunogenic studies showed that the formulation based onbiodegradable polymeric microspheres is able to elicit, with a single dose, an immune response and protection similar to that attained with 3 doses of conventional Bm86 vaccine formulations.

Os carrapatos são artrópodes hematófagos, vetores de doenças. Vacinas são uma alternativa para o seu controle, já que esses parasitas durante a infestação, estimulam as respostas imunes do hospedeiro, as quais são implicadas em sua rejeição. As glândulas salivares do parasita são importantes para permitir a alimentação e para mediar os mecanismos de escape às defesas do hospedeiro. Diversas evidências indicam que ocorre reatividade cruzada entre espécies de carrapatos e que reações de hipersensibilidade cutânea tardia (DTH) são correlacionadas com resistência ao carrapato. A possibilidade de vacinar cachorros que são parasitados pelo R. sanguineus com antígenos do carrapato do boi, o R microplus, foi investigada por meio da análise in silico de 45 GIs de R microplus clonados em vetor plasmidial (TOPO VR2001), dentre os quais 14 Gls de R microplus se revelaram mais similares a sequências do R sanguineus, e foram empregados para avaliar: 1) A capacidade em elicitar reações cutâneas tardias em cobaias imunes a carrapatos por meio de infestações prévias com R sanguineus. 2) A capacidade de vacinas contendo GIs individuais em afetar infestações de camundongos com adultos de R sanguineus. 3) a capacidade do GI induzir anticorpos específicos após vacinação em camundongos. Dos 14 GIs testados, apenas dois não induziram reações cutâneas, quatro não afetaram nenhum parâmetro parasitológico da infestação, e três não induziram a produção de anticorpos nesses animais. Dentre os GIs, sete foram escolhidos para compor uma vacina multigênica contra o carrapato do cão R sanguineus. A vacina foi capaz de induzir resistência á infestação por R sanguineus em camundongos e em cachorros vacinados evidenciadoa pela diminuição do número de fêmeas que conseguiram colocar ovos, do peso médio da massa de ovos produzidos por essas fêmeas, do índice reprodutivo dessas fêmeas, e da taxa de eclosão das larvas, demonstrando que GIs de R microplus podem ser alvos para formulação de uma vacina contra o carrapato R sanguineus. Ticks are arthropod vectors of disease. Vaccines are an alternative to chemicals for controlling ticks because during infestations these parasites stimulate host immune responses such as delayed hypersensitivity skin reactions (DTH), which are involved in their rejection and are correlated with resistance to ticks. Tick salivary glands are important for the parasite to acquire blood meals because their products mediate escape mechanisms from host defenses. The possibility of vaccinating dogs against infestations with the brown dog tick, Rhipicephalus sanguineus, with antigens derived from salivary glands of the cattle tick, R. microplus, was investigated by in silica analysis of 45 genes from R. microplus. These genes were targeted because of their putative biological function and had been cloned into the plasmid vector TOPO VR2001. Of them, 14 were chosen to be evaluated in a vaccine because their sequences were the most similar to several genes expressed in salivary glands of R. sanguineus. The plasmids containing the genes of interest (GIs) were used to assess: 1) The ability of the product of the genes to elicit delayed skin reactions in guinea pigs immune to ticks by previous infestations with R sanguineus. 2) The ability of individual GIs delivered as DNA vaccines to affect infestations of mice with adult R sanguineus. 3) The ability of the genes to induce specific antibodies after vaccination in mice. Only two of the 14 genes delivered to guinea pigs via intradermal injection of DNA did not elicit delayed skin reaction, four used in a vaccine did not affect any parameter of tick infestations, and three did not induce production of antibodies in these animals after DNA vaccination. Of the 14 genes, seven were chosen to formulate a multigene vaccine against the dog tick R. sanguineus. The vaccine was able to significantly affect several parameters of infestations by R sanguineus in vaccinated dogs and mice. This was reflected in the reduction of the number of females that were able to lay eggs, of the average weight of the egg mass produced by these females, of the reproductive rate of these females, and of hatching rate of larvae, demonstrating that GIs from R microplus may be targets for development of a vaccine against the tick R sanguineus.

A Neoplasia Mieloproliferativa Crônica (NMPC)- Politemia Vera é uma desordem clonal caracterizada pelo acúmulo de eritrócitos, leucócitos, plaquetas e progenitores normais na ausência de um estímulo definido. Apesar dos avanços no diagnóstico de PV e da descrição de mecanismos envolvidos no estabelecimento da doença sua patogênese permanece desconhecida entretanto, alterações no mecanismo regulador da apoptose parecem estar envolvidos em sua fisiopatologia. A compreensão acerca do funcionamento da maquinaria apoptótica e sua possível regulação por microRNAs em pacientes com Policitemia Vera parece revelar novos alvos para estudo e consequentemente transformar-se em novas terapias para a doença. Neste contexto os objetivos deste trabalho foram avaliar em leucócitos de sangue periférico e células CD34+ de medula óssea dos pacientes de PV: (1) a quantificação da expressão de microRNAs cujos alvos são RNAs associados a regulação da apoptose; (2) Correlação dos níveis de expressão dos miRNAs com os de RNAm das moléculas pró e antiapoptóticas da família Bcl-2 e dos receptores de morte; (3) Correlação dos níveis de expressão dos miRNAs com os seguintes dados clínico-laboratoriais dos pacientes: concentração de hemoglobina, hematócrito e percentagem da mutação JAK2. Os pacientes com Policitemia Vera apresentam aumento de expressão dos microRNAs 29c, 16, 21, 26a, 130b e let-7d e diminuição de miR15a e 34c em leucócitos de sangue periférico; Aumento de expressão dos miRs 29c, 16 e 21; diminuição na expressão de miR 130b e let-7d em células CD34+ ; alteração na expressão de genes pró e anti-apoptóticos em leucócitos de sangue periférico com aumento de a1, mcl-1 e diminuição de bcl-2, ciap-2, bax e fas-L,alteração na expressão de genes pró e anti-apoptóticos em células CD34+ com aumento de expressão de fas, bid, mcl-1, bcl-xl e c-flip; diminuição na expressão de bik. Observamos diminuição na expressão protéica de BCL-2 em pacientes quando comparado aos indivíduos controle.Notamos também a correlação entre a alteração na expressão de microRNAs e seus respectivos genes alvo e destes com parâmetros hematológicos analisados. Os linfócitos dos pacientes de PV apresentam maior resistência a apoptose do que os indivíduos controles quando induzidos por: Actinomicina, etoposídeo, citarabina e cicloheximida. Concluindo, os dados obtidos sugerem a participação dos microRNAs na regulação da maquinaria apoptótica e a participação desta desregulação na fisiopatologia da PV. Estes resultados contribuem para o melhor entendimento da fisiopatologia da PV e serão úteis futuramente para o desenho de novos alvos terapêuticos e descrição de marcadores de prognóstico. Polycythaemia vera (PV) is a clonal disorder characterized by an accumulation of normal red and white cells, platelets, and their progenitors in absence of a definable stimulus. Despite the advances in PV diagnosis and the description of the mechanisms involved in disease establishment its pathogenesis remains unclear. The apoptosis deregulation might have a role in PV physiopathology. Fully understanding the basic apoptotic pathway and its potential regulation by microRNA in PV patients cells might unveil targets for manipulation, which may be translated into novel therapies for disease.The aims of this study were to avaluate in leukocytes and CD34+ cells: (1) The microRNA expression whose RNA target are associated with apoptosis regulation (2) Correlation between microRNA expression and the mRNA levels of anti and pro-apoptotic family Bcl-2 expression and death receptors; (3) Correlation between microRNA expression and the clinical data of patients: hemoglobin concentration, hematocrit and JAK2 percentage. Patientes with Polycythemia Vera shows increased expression of microRNAs 29c, 16, 21, 26a, 130b and let-7d and 34c and 15a decrease in peripheral leukocytes; incresead expression of miRs 29c, 16 and 21, decrease in miR130b and let-7d expression in CD34+ cells; deregulation in pro and anti-apoptotic gene expression in peripheral leukocytes with increase in a1, mcl-1 and decrease in bcl-2, ciap-2, bax and fas-L, deregulation in pro and anti-apoptotic gene expression in CD34+ cells with increased expression of fas, bid, mcl-1, bcl-xl and c-flip and decreased expression of bik. Decreased in proteic expression of BCL-2 in peripheral leukocytes of patients when compared to controls. Correlation between de deregulated expression of microRNA and their genes target and those with hematological parameters. Lymphocytes from PV patients shows higher resistance to apoptosis than controls when induced by: Actinomicin, etoposide, cytarabine and cycloheximide. In conclusion the data suggest the involvement of microRNA in apoptosis regulation and the involvement of apoptosis machinery in the PV pathophysiology. These results will contribute for a better understanding of PV pathophysiology and will be useful for the discover of future therapies.

Leucotrienos e prostaglandinas são metabólitos do ácido araquidônico que, além de mediadores da inflamação são importantes imunomoduladores da liberação de citocinas, nas respostas imune inata e adquirida. Embora estes mediadores apresentem potencial para serem utilizados como adjuvantes ou imunomoduladores da resposta imune, eles são altamente instáveis, dificultando o uso in vivo. Por esta razão, estas substâncias foram incorporadas em um sistema polimérico microestruturado. Este foi constituído de microesferas de quatro a seis micrômetros de diâmetro, contendo leucotrieno B4 (LTB4) ou prostaglandina E2 (PGE2) incorporados na matriz polimérica (PLGA). A caracterização in vitro das microesferas de PLGA, contendo LTB4 ou PGE2, foi feita através da determinação da morfologia e medida dos diâmetros médios, taxa de encapsulação e perfil de liberação in vitro dos mediadores. Além disso, foi avaliada a preservação da atividade biológica do LTB4 liberado das microesferas, através do efeito do mesmo sobre a expressão de moléculas de adesão Mac-1 por citometria de fluxo. Também foram avaliadas a preservação da atividade biológica do LTB4 e da PGE2 liberados do interior das microesferas, através de estudos com microscopia intravital e a ativação de células endoteliais humanas (HUVECs e HUAECs). Realizamos ainda, ensaio de fagocitose com as microesferas contendo os dois mediadores encapsulados, utilizando macrófagos peritoneais murinos, além da avaliação da sobrevivência dos animais tratados intranasalmente com microesferas contendo LTB4 ou PGE2 durante a infecção pelo H. capulatum. Nestes animais, avaliamos a reação inflamatória pulmonar, o número de UFCs recuperadas dos pulmões e a modulação da resposta imune, através da quantificação de citocinas inflamatórias. Os estudos abordados neste trabalho revelaram achados interessantes e importantes quanto ao uso de microesferas biodegradáveis contendo mediadores lipídicos em situação de terapia, especialmente quando estes estão envolvidos em processos inflamatórios e/ou infecciosos. Leukotrienes and prostaglandins are arachidonic acid metabolites, which participate in the inflammatory response and modulate cytokines release in both adaptive and innate immune responses. However, some physicochemical characteristics of these mediators, such as poor solubility in water and chemical instability, make them difficult to administer in vivo. In this sudy, we developed a polymeric microparticulate system for the encapsulation of lipid mediators. Regarding the in vitro characterization of the microspheres, we determined their diameters, evaluated the in vitro release of the mediators and the microspheres uptake by peritoneal macrophages. To assess the preservation of the biological activities of these mediators, we conducted intravital microscopy studies and determined the effect of LTB4 and PGE2-loaded biodegradable microspheres on inflammatory mediators release by murine peritoneal macrophages and human endothelial cells. In mice infected by H. capsulatum, we investigated the effects of intranasal administration of the microspheres on pulmonary inflammatory response. In this context, we analyzed the inflammatory cells recruited to the bronchoalveolar space, the mice survival and the number of CFUs recovered from the lungs after the administrations. We also assessed the cytokines release by the lung cells after the treatment with microspheres during the course of the infection. In conclusion, our findings showed that biodegradable microspheres could preserve the biological activity of the encapsulated mediators indicating their use as a new strategy to modulate cell activation, especially in the innate immune response.